Methylene Blue
Active ingredient · 2 therapeutic classes
Sold as COLLYRE BLEU LAITER · Methylthioninium chloride… · METHYLENE BLEU LIQ 1%
- Drug class
- Antidotes
- Availability
- See label
- Routes
- Intravenous, Ophthalmic, Oral
- Markets covered
- 3
- Products on record
- 9
Overview
Methylene Blue is an active pharmaceutical ingredient in the Antidotes group (V03AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 15, 2026 |
| EU European Union | EMA | 2 | December 19, 2025 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
GBUnited Kingdom· MHRA
3 products
Uses
1).
How to take
EUEuropean Union· EMA
2 products
Uses
Acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia. Methylthioninium chloride Proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old).
How to take
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (2)
Drug interactions
Known interactions involving Methylene Blue. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB444520006 · revised December 29, 2025
- [2]European Medicines Agency · EMEA/H/C/002108 · revised December 19, 2025
- [3]Health Canada (DPD) · 00050466 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.